RxDoctor Payments Data

Peter Bosco, MD

Urology · Hartford, CTNPI 1992725683

Payments from drug & device makers

$3,280in general payments, 2019–2025

Across 152 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$467
  • Johnson & Johnson$345
  • Bayer$313
  • Sumitomo Pharma America, Inc.$256
  • Astellas Pharma US Inc$248
  • Merck$231
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,05793%
  • Education$2237%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,280 in reported general payments places this provider in the 60th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$141,196
Medicare patients
438
Services billed
2,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide23$323,467
OrgovyxRelugolix84$251,089
ErleadaApalutamide13$194,130
MyrbetriqMirabegron142$168,398
GemtesaVibegron127$128,788
Tamsulosin Hcl1,274$17,690
Mirabegron ErMirabegron17$12,683
Potassium Citrate ErPotassium Citrate87$8,072
Finasteride734$7,544
Dutasteride279$6,931
Alfuzosin Hcl ErAlfuzosin Hcl138$3,577
Oxybutynin Chloride80$1,988
Solifenacin Succinate69$1,917
NitrofurantoinNitrofurantoin Macrocrystal58$1,599
Bicalutamide32$1,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$248$491,866165 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$256$379,877211 claims
Johnson & JohnsonErleada$345$194,13013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 156 urology providers in Connecticut.

Other urology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →